Menu

FDA Approves Second CAR T-Cell Therapy

The therapy, produced by Kite Pharma and owned by Gilead Sciences, is approved for use against some types of large B-cell lymphomas. 

Oct 19, 2017
Ashley P. Taylor

ISTOCK, 7ACTIVESTUDIOThe Food and Drug Administration yesterday (October 18, 2017) approved the chimeric antigen receptor (CAR) T-cell therapy Yescarta to treat patients with certain types of large B-cell lymphomas who have relapsed or not responded to two other types of cancer treatments. It is the second CAR T-cell therapy approved in the U.S.

“Today marks another milestone in the development of a whole new scientific paradigm for the treatment of serious diseases. In just several decades, gene therapy has gone from being a promising concept to a practical solution to deadly and largely untreatable forms of cancer,” FDA Commissioner Scott Gottlieb says in a statement.

“There will likely be thousands of lives saved in the next few years because of it,” David Maloney, medical director of cellular immunotherapy at Fred Hutchinson Cancer Research Center, tells NBC News.

CAR T-cell therapies work by engineering a patient’s own immune cells to target cancer cells.

See “The CAR T-Cell Race

In August, the FDA approved a CAR T-cell therapy, Kymriah, produced by Novartis, for acute lymphoblastic leukemia. Like Yescarta, Kymriah was also approved only for patients for whom other therapies have twice failed.

Development of the treatment began at the National Cancer Institute, then moved to Kite in 2012, The New York Times reports. Gilead acquired Kite in August. The FDA granted the approval to Kite, which will continue to produce the drug. That process, which takes about 17 days, involves shipping a patient’s cells to Kite’s cell-processing facility in California where they will be engineered, then freezing the cells and shipping them back to the patient’s hospital, according to The New York Times.

Patients with large B-cell lymphoma who were treated with Yescarta had a 51 percent complete remission rate in a multicenter clinical trial, according to the FDA statement.

The treatment comes with the risk of life-threatening side effects, including “high fevers, crashing blood pressure, lung congestion and neurological problems,” The New York Times reports. It also very expensive, with a list price of $373,000, according to a Kite Pharma release.

“Yes, it can pose life threatening problems,” Tina Bureau, who took Yescarta as part of the clinical trial and whose lymphoma is in remission, tells The New York Times. “But when you’re in a situation where your life’s threatened anyway, I don’t feel you have anything to lose.”

See “Marking CAR T-Cell Therapy Safer

“Together, Gilead and Kite will accelerate studies of CAR-T therapy in multiple blood cancers and advance other cell therapy approaches for solid tumors,” David Chang, chief medical officer at Kite, tells The Times of Israel, “with the goal of helping patients with diverse cancers benefit from this new era of personalized cancer therapy.”

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!